Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Biosimilar Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Global Biosimilar Market Outlook 2022- 2027

The biosimilar market size reached US$ 13.0 Billion in 2021. This market is currently being driven by a number of factors such as patent expires of blockbuster biological drugs, lower prices, rising prevalence of chronic diseases, and cost-saving initiatives from governments and third-party payers. Catalyzed by these factors, the market is expected to reach US$ 60.8 Billion by 2027, exhibiting a growth rate (CAGR) of 26.1% during 2022-2027. 

 

 
 

www.imarcgroup.com

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

Biosimilars, also known as follow-on biologics, refers to a biotherapeutic product which is highly similar to a reference biologic drug. It is produced using living organisms or cells and has a complex molecular structure. When the patent of a biologic drug expires, manufacturers resort to the approval from the regulatory authorities so as to start the production of biosimilars. For being labelled as a biosimilar, a biological drug should be proved similar in terms of quality, safety and efficacy. In comparison with generic drugs, biosimilars are expensive as their production process is more complex and requires higher investment in research and development.

Global Biosimilar Industry Drivers/Constraints:

  • Over the years, the patents of several blockbuster biologic drugs have expired and a number of blockbuster drugs are further expected to lose patent protection in the coming years. This is expected to provide tremendous opportunities for biosimilar manufacturers in the near future.
  • Cost-saving initiatives undertaken by governments and third-party payers have encouraged the use of biosimilars over branded biologics, thereby propelling the demand of biosimilars.
  • Some of the other factors bolstering the demand for biosimilars include cost-effectiveness, rising prevalence of chronic diseases (such as autoimmune diseases and cancer) and growing geriatric population.
  • There are some factors hampering the biosimilars market growth. This includes negative perception from physicians, patent extensions, lower price differential compared to small-molecule generics, etc.


Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global biosimilar market report, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on molecule, indication and manufacturing type.

Molecule insights:                   

  • Infliximab
  • Insulin Glargine
  • Epoetin Alfa
  • Etanercept
  • Filgrastim
  • Somatropin
  • Rituximab
  • Follitropin Alfa
  • Adalimumab
  • Pegfilgrastim
  • Trastuzumab
  • Bevacizumab
  • Others
     

On the basis of the molecule, the market has been segmented as Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab, Pegfilgrastim, Trastuzumab, Bevacizumab, and Others.

Indication Insights:

 

 
 

www.imarcgroup.com

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

  • Auto-Immune Diseases
  • Blood Disorder
  • Diabetes
  • Oncology
  • Growth Deficiency
  • Female Infertility
  • Others
     

On the basis of the indication, the market has been segmented as Auto-Immune Diseases, Blood Disorders, Diabetes, Oncology, Growth Deficiency, Female Infertility, and Others.

Manufacturing Type Insights:

  • In-house Manufacturing
  • Contract Manufacturing
     

Based on the type of manufacturing, the market is segregated into in-house manufacturing and contract manufacturing. Amongst these, in-house manufacturing accounts for the majority of the market share.

Regional Insights:

  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Rest of Europe
  • United States
  • Japan
  • India
  • South Korea
  • Others
     

Region-wise, the market has been segmented into Europe (Germany, France, Italy, Spain, the United Kingdom and Rest of Europe), the United States, Japan, India, South Korea and Others.

Competitive Landscape:

The competitive landscape of the global biosimilar market has also been analysed. Some of the leading players operating in the market are:

  • Sandoz International GmbH
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Limited
  • Celltrion Inc.
  • Biocon Limited
  • Samsung Biologics
  • Amgen, Inc.
  • Dr. Reddy's Laboratories Limited
  • Stada Arzneimittel Ag
     

This report provides a deep insight into the global biosimilars market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the biosimilars market in any manner.

Report Coverage:

Report Features Details
Base Year of the Analysis 2021
Historical Period 2016-2021
Forecast Period 2022-2027
Units US$ Billion
Segment Coverage Molecule, Indication, Manufacturing Type, Region
Region Covered Europe (Germany, France, Italy, Spain, United Kingdom, Rest of Europe), United States, Japan, India, South Korea and Others
Companies Covered Sandoz International GmbH, Pfizer Inc., Teva Pharmaceutical Industries Limited, Celltrion Inc., Biocon Limited, Samsung Biologics, Amgen, Inc., Dr. Reddy's Laboratories Limited and Stada Arzneimittel Ag
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3999
Five User License: US$ 4500
Corporate License: US$ 4999
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

1   Preface
2   Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3   Executive Summary
4   Biosimilar Market – Introduction

    4.1    Overview
    4.2    WHO and FDA Terminology on Biosimilars
    4.3    Biosimilars and Generics
    4.4    Biosimilars and Branded Biological Products
5   Why are Biosimilars So Lucrative?
    5.1    Patent Expiry of Blockbuster Biological Drugs
    5.2    Significant Price Differential between Biosimilars and Innovator Drugs
    5.3    Savings for the Government and Third Party Payers
    5.4    Rising Prevalence of Lifestyle Diseases
    5.5    Incentives for Prescribers, Pharmacists and Patients
    5.6    Emergence of New Players in Europe and Emerging Markets
    5.7    Increasing Product Differentiation as Manufacturers Tie-Up with Drug Delivery Device Companies
6   Biosimilar Research, Development and Manufacturing
    6.1    Research and Development: Biosimilars vs. Innovator Drugs
    6.2    Manufacturing: Biosimilars vs. Innovator Drugs
7   Biosimilar Market
    7.1    Market Overview
    7.2    Historical Performance
    7.3    Impact of COVID-19
    7.4    Market Breakup by Segment
    7.5    Market Breakup by Manufacturing Type
    7.6    Market Breakup by Indication
    7.7    Market Breakup by Region
    7.8    Market Forecast
    7.9    Biosimilar Patent Landscape
        7.9.1    Patent Landscape in the US
        7.9.2    Patent Landscape in Europe
        7.9.3    Patent Landscape in Japan
    7.10    SWOT Analysis
        7.10.1    Overview
        7.10.2    Strengths
        7.10.3    Weaknesses
        7.10.4    Opportunities
        7.10.5    Threats
    7.11    Value Chain Analysis
        7.11.1   Characterizing the Existing Innovator Drug
        7.11.2   Research and Development
            7.11.2.1    Characterization of Biosimilars
            7.11.2.2    Developing a Unique Cell Line
        7.11.3   Product Development
            7.11.3.1    Pre-Testing
            7.11.3.2    Intermediary Clinical Testing (PK/PD)
            7.11.3.3    Confirmatory Clinical Phase-III
        7.11.4   Final Product Formulation
        7.11.5   Marketing and Distribution
   7.12    Porter’s Five Forces Analysis
        7.12.1    Overview
        7.12.2    Bargaining Power of Buyers
        7.12.3    Bargaining Power of Suppliers
        7.12.4    Degree of Competition
        7.12.5    Threat of New Entrants
        7.12.6    Threat of Substitutes
    7.13    Price Analysis
        7.13.1    Key Price Indicators
        7.13.2    Price Trends
        7.13.3    Margin Analysis
8   Market Breakup by Molecule
    8.1    Infliximab
    8.2    Insulin Glargine
    8.3    Epoetin Alfa
    8.4    Etanercept
    8.5    Filgrastim
    8.6    Somatropin
    8.7    Rituximab
    8.8    Follitropin Alfa
    8.9    Adalimumab
    8.10    Pegfilgrastim
    8.11    Trastuzumab
    8.12    Bevacizumab
    8.13    Others
9   Market Breakup by Manufacturing Type
    9.1    In-house Manufacturing
        9.1.1    Market Trends
        9.1.2    Market Forecast
    9.2    Contract Manufacturing
        9.2.1    Market Trends
        9.2.2    Market Forecast
10  Market Breakup by Indication
    10.1    Auto-Immune Diseases
        10.1.1    Market Trends
        10.1.2    Market Forecast
    10.2    Blood Disorder
        10.2.1    Market Trends
        10.2.2    Market Forecast
    10.3    Diabetes
        10.3.1    Market Trends
        10.3.2    Market Forecast
    10.4    Oncology
        10.4.1    Market Trends
        10.4.2    Market Forecast
    10.5    Growth Deficiency
        10.5.1    Market Trends
        10.5.2    Market Forecast
    10.6    Female Infertility
        10.6.1    Market Trends
        10.6.2    Market Forecast
    10.7    Others
        10.7.1    Market Trends
        10.7.2    Market Forecast
11  Market Breakup by Region
    11.1    Europe
        11.1.1    Market Performance
        11.1.2    Key Players and Biosimilars
        11.1.3    Market Breakup by Country
        11.1.4    Market Forecast
        11.1.5    Italy
            11.1.5.1     Market Performance
            11.1.5.2     Key Players and Biosimilars
            11.1.5.3     Market Forecast
        11.1.6    Germany
            11.1.6.1     Market Performance
            11.1.6.2     Key Players and Biosimilars
            11.1.6.3     Market Forecast
        11.1.7    France
            11.1.7.1     Market Performance
            11.1.7.2     Key Players and Biosimilars
            11.1.7.3     Market Forecast
        11.1.8    United Kingdom
            11.1.8.1     Market Performance
            11.1.8.2     Key Players and Biosimilars
            11.1.8.3     Market Forecast
        11.1.9    Spain
            11.1.9.1     Market Performance
            11.1.9.2     Key Players and Biosimilars
            11.1.9.3     Market Forecast
        11.1.10    Rest of Europe
            11.1.10.1   Market Performance
            11.1.10.2   Market Forecast
    11.2    United States
        11.2.1    Current Market Trends
        11.2.2    Key Players and Biosimilars
        11.2.3    Market Forecast
    11.3    Japan
        11.3.1    Market Performance
        11.3.2    Key Players and Biosimilars
        11.3.3    Market Forecast
    11.4    India
        11.4.1    Current Market Trends
        11.4.2    Key Players and Biosimilars
        11.4.3    Market Forecast
    11.5    South Korea
        11.5.1    Current Market Trends
        11.5.2    Key Players and Biosimilars
        11.5.3    Market Forecast
    11.6    Rest of the World
        11.6.1    Current Market Trends
        11.6.2    Market Forecast
12  Requirements for Setting Up a Biosimilar Manufacturing Plant
    12.1    Manufacturing Process
    12.2    Raw Material Requirements
    12.3    Raw Material Pictures
    12.4    Land and Construction Requirements
    12.5    Machinery and Infrastructure Requirements
    12.6    Machinery Pictures
    12.7    Plant Layout
    12.8    Packaging Requirements
    12.9    Utility Requirements
    12.10    Manpower Requirements
13  Competitive Landscape
    13.1    Market Structure
    13.2    Key Players
    13.3    Profiles of Key Players
        13.3.1    Sandoz International GmbH
        13.3.2    Pfizer Inc.
        13.3.3    Teva Pharmaceutical Industries Limited 
        13.3.4    Celltrion Inc. 
        13.3.5    Biocon Limited
        13.3.6    Samsung Biologics 
        13.3.7    Amgen, Inc.
        13.3.8    Dr. Reddy's Laboratories Limited
        13.3.9    Stada Arzneimittel Ag

List of Figures

Figure 1: Global: Biosimilar Market: Sales Value (in Billion US$), 2016-2021
Figure 2: Global: Biosimilar Market: Breakup by Molecule (in %), 2021
Figure 3: Global: Biosimilar Market: Breakup by Manufacturing Type (in %), 2021
Figure 4: Global: Biosimilar Market: Breakup by Indication (in %), 2021
Figure 5: Global: Biosimilar Market: Breakup by Region (in %), 2021
Figure 6: Global: Biosimilar Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 7: Global Biosimilars Industry: SWOT Analysis
Figure 8: Global: Biosimilar Industry: Value Chain Analysis
Figure 9: Global: Biosimilars Industry: Porter’s Five Forces Analysis
Figure 10: Global: Biosimilar Market: Average Price Trends of Inflectra
Figure 11: Global: Biosimilar Market: Average Price Trends of Zarxio
Figure 12: Biosimilars Industry: Breakup of Profit Margins at Various Level of the Value Chain
Figure 13: Infliximab: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 14: Infliximab: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Insulin Glargine: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 16: Insulin Glargine: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Epoetin Alfa: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 18: Epoetin Alfa: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Etanercept: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 20: Etanercept: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Filgrastim: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 22: Filgrastim: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Somatropin: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 24: Somatropin: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: Rituximab: Biosimilar Market: Sales Value (in Million US$), 2017-2021
Figure 26: Rituximab: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Follitropin Alfa: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 28: Follitropin Alfa: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Adalimumab: Biosimilar Market: Sales Value (in Million US$), 2018-2021
Figure 30: Adalimumab: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: Pegfilgrastim: Biosimilar Market: Sales Value (in Million US$), 2019-2021
Figure 32: Pegfilgrastim: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: Trastuzumab: Biosimilar Market: Sales Value (in Million US$), 2018-2021
Figure 34: Trastuzumab: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Bevacizumab: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 36: Others: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: In-House Manufacturing: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 38: In-House Manufacturing: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: Contract Manufacturing: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 40: Contract Manufacturing: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: Global: Biosimilar Market (Autoimmune Diseases): Sales Value (in Million US$), 2016 & 2021
Figure 42: Global: Biosimilar Market Forecast (Autoimmune Diseases): Sales Value (in Million US$), 2022-2027
Figure 43: Global: Biosimilar Market (Blood Disorders): Sales Value (in Million US$), 2016 & 2021
Figure 44: Global: Biosimilar Market Forecast (Blood Disorders): Sales Value (in Million US$), 2022-2027
Figure 45: Global: Biosimilar Market (Diabetes): Sales Value (in Million US$), 2016 & 2021
Figure 46: Global: Biosimilar Market Forecast (Diabetes): Sales Value (in Million US$), 2022-2027
Figure 47: Global: Biosimilar Market (Oncology): Sales Value (in Million US$), 2016 & 2021
Figure 48: Global: Biosimilar Market Forecast (Oncology): Sales Value (in Million US$), 2022-2027
Figure 49: Global: Biosimilar Market (Growth Deficiency): Sales Value (in Million US$), 2016 & 2021
Figure 50: Global: Biosimilar Market Forecast (Growth Deficiency): Sales Value (in Million US$), 2022-2027
Figure 51: Global: Biosimilar Market (Female Infertility): Sales Value (in Million US$), 2016 & 2021
Figure 52: Global: Biosimilar Market Forecast (Female Infertility): Sales Value (in Million US$), 2022-2027
Figure 53: Global: Biosimilar Market Forecast (Others): Sales Value (in Million US$), 2022-2027
Figure 54: Europe: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 55: Europe: Biosimilar Market: Breakup by Country (in %), 2021
Figure 56: Europe: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: Italy: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 58: Italy: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: Germany: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 60: Germany: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: France: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 62: France: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: United Kingdom: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 64: United Kingdom: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Spain: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 66: Spain: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: Rest of Europe: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 68: Rest of Europe: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 69: United States: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 70: United States: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 71: Japan: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 72: Japan: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 73: India: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 74: India: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 75: South Korea: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 76: South Korea: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 77: Others: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 78: Others: Biosimilar Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 79: Biosimilar Manufacturing: Detailed Process Flow
Figure 80: Biosimilar Manufacturing Plant: Raw Materials Requirement
Figure 81: Biosimilar Manufacturing Process: Conversion Rates of Feedstocks
Figure 82: Biosimilar Manufacturing Plant: Machinery Costs (in US$)
Figure 83: Biosimilar Manufacturing Plant: Primary Packaging
Figure 84: Biosimilar Manufacturing Plant: Secondary Packaging
Figure 85: Biosimilar Manufacturing Plant: Tertiary Packaging 

List of Tables

Table 1: Global: Sales and Patent Expiry of Blockbuster Biological Drugs (in Million US$), 2017
Table 2: Global: Biosimilar Market: Biosimilars Vs Innovators Drug Development
Table 3: Global: Biosimilar Market: Biosimilars Vs Biologics Manufacturing
Table 4: Global: Biosimilar Market: Key Industry Highlights, 2021 and 2027
Table 5: US: Biosimilar Market: Patent Landscape
Table 6: Europe: Biosimilar Market: Patent Landscape
Table 7: Japan: Biosimilar Market: Patent Landscape
Table 8: Global: Biosimilar Market: Price Comparison Between Biosimilar and Originator Drugs
Table 9: Global: Biosimilar Market: Breakup by Molecule (in Million US$), 2022-2027
Table 10: Global: Infliximab: Brand & Biosimilar Market Overview
Table 11: Global: Insulin Glargine: Brand & Biosimilar Market Overview
Table 12: Global: Epoetin Alfa: Brand & Biosimilar Market Overview
Table 13: Global: Etanercept: Brand & Biosimilar Market Overview
Table 14: Global: Filgrastim: Brand & Biosimilar Market Overview
Table 15: Global: Somatropin: Brand & Biosimilar Market Overview
Table 16: Global: Rituximab: Brand & Biosimilar Market Overview
Table 17: Global: Follitropin Alfa: Brand & Biosimilar Market Overview
Table 18: Global: Adalimumab: Brand & Biosimilar Market Overview
Table 19: Global: Pegfilgrastim: Brand & Biosimilar Market Overview
Table 20: Global: Trastuzumab: Brand & Biosimilar Market Overview
Table 21: Global: Bevacizumab: Brand & Biosimilar Market Overview
Table 22: Global: Biosimilar Market Forecast: Breakup by Manufacturing Type (in Million US$), 2022-2027
Table 23: Global: Biosimilar Market Forecast: Breakup by Indication (in Million US$), 2022-2027
Table 24: Global: Biosimilar Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 25: Europe: Biosimilar Market: Key Players and Biosimilars
Table 26: Italy: Biosimilar Market: Key Players and Biosimilars
Table 27: Germany: Biosimilar Market: Key Players and Biosimilars
Table 28: France: Biosimilar Market: Key Players and Biosimilars
Table 29: United Kingdom: Biosimilar Market: Key Players and Biosimilars
Table 30: Spain: Biosimilar Market: Key Players and Biosimilars
Table 31: United States: Biosimilar Market: Key Players and Biosimilar
Table 32: United States: Biosimilar Market: Launch of Expected Biosimilar
Table 33: Japan: Biosimilar Market: Key Players and Biosimilars
Table 34: India: Biosimilar Market: Key Players and Biosimilars
Table 35: South Korea: Biosimilar Market: Key Players and Biosimilar
Table 36: Biosimilar Manufacturing Plant: Manpower Requirements
Table 37: Biosimilar Market: Competitive Structure
Table 38: Global: Biosimilar Market: Key Players


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Key Questions Answered in This Report

The global biosimilar market was valued at US$ 13.0 Billion in 2021.

We expect the global biosimilar market to exhibit a CAGR of 26.1% during 2022-2027.

The rising prevalence of various chronic diseases, along with the continuous patent expiry of
numerous blockbuster biologic drugs, is primarily driving the global biosimilar market.

The sudden outbreak of the COVID-19 pandemic had led to the delay in clinical trials for biosimilars
due to the rising focus on the production of effective vaccines against coronavirus infection, thereby
negatively impacting the market for biosimilars.
 

Based on the molecule, the global biosimilar market has been bifurcated into Infliximab,
Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin
Alfa, Adalimumab, Pegfilgrastim, Trastuzumab, Bevacizumab, and Others.

Based on the indication, the global biosimilar market has been divided into auto-Immune
diseases, blood disorders, diabetes, oncology, growth deficiency, female infertility, and others.

Based on the manufacturing type, the global biosimilar market has been classified into in-house
manufacturing and contract manufacturing. Currently, in-house manufacturing accounts for the
largest market share.

On a regional level, the market has been classified into the Europe (Germany, France,
Italy, Spain, United Kingdom, Rest of Europe), United States, Japan, India, South Korea,
and others

Some of the major players in the global biosimilar market include Sandoz International
GmbH, Pfizer Inc., Teva Pharmaceutical Industries Limited, Celltrion Inc., Biocon Limited,
Samsung Biologics, Amgen, Inc., Dr. Reddy's Laboratories Limited and Stada Arzneimittel Ag.

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 3999

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links

4